There is broad consensus that the development of new medical interventions takes too long, costs too much and too often ends in failure. Furthermore, the 'innovation gap' between fundamental discoveries related to human disease and the delivery of new therapeutic options to patients has remained stubbornly persistent.
However, the field of translational science is poised to provide solutions to bridge this gap and thereby help to bring more medicines to more patients more quickly. This article aims to increase the awareness of the burgeoning field of translational science as a discipline, and introduces a nascent international collaborative effort in this arena.
Defining translational science
Translation is defined as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public -ranging from therapeutics and diagnostics to medical procedures and behavioural changes. However, this process is poorly understood scientifically and often dislocated within and between organizations. This contributes substantially to the high failure rate of translation, indicating the need for systematic study. Here, we define translational science as the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process.
A new player arrives There has been a rapid growth of opportunities for translation of biomedical research over the past decade and a half, aided by the development of ever-higherthroughput technologies, such as next-generation sequencing platforms, to probe biological systems. Running counter to this growth of basic research knowledge, however, has been a reduction of internal resourcing of the earliest stages of preclinical drug discovery research by large pharmaceutical companies.
Realization that a new type of organization was needed to serve as an 'adaptor' and 'de-risker' between basic research and commercial organizations led to the creation of dedicated translational science organizations by governments, non-profit organizations and researchers in multiple countries. Between 2000 and 2011, MRC Technology (MCRT) in the UK, the European Infrastructure for Translational Medicine (EATRIS) in the European Union, the Centre for Drug Research and Development (CDRD) in Canada, Therapeutic Innovation Australia (TIA), and the National Center for Advancing Translational Sciences (NCATS) in the United States (Supplementary information S1 (box)) were established to catalyse the translational process and accelerate therapeutic innovation.
Despite their geographic diversity and somewhat country-specific mandates, our organizations approach translational science with a shared mindset and use common language to describe the nature of the opportunities and challenges in the field. There is also consensus among our organizations concerning the need to raise the level of awareness and understanding of translation and translational science among basic scientists, funders, policy makers and patients, and their associated communities. The organizations therefore agreed to establish a collaborative effort to leverage the experience, expertise and credibility of each and promote translational science with a unified voice globally.
Increasing awareness
Scientists engaged in basic biomedical research provide the foundation for translational developments. However, such researchers are often not aware of the nature and complexity of the steps required for a promising discovery or technology to advance to the clinic. Only a small percentage of projects from traditional academic and nonprofit research laboratories have progressed to a point sufficient to incentivize and attract the capital investment necessary to progress into preclinical and clinical testing. Global collaboration in translational science promises to accelerate the discovery, development and dissemination of new medical interventions. Here, we introduce a new international collaboration of translational science organizations and highlight our initial strategy to reduce or remove bottlenecks in translation.
To address this failure to progress, each of our organizations provides collaborative scientific and technical expertise and resources to basic researchers to de-risk discoveries to a point at which a company can either be formed or will license the technology for further development (Supplementary information S1 (box)). For those basic scientists who wish to see their discoveries advance to the clinic, acquiring a thorough understanding of the processes, core competencies, and technical and financial resources necessary is crucial, and our organizations provide educational resources for this purpose as well (Supplementary information S1 (box)).
Policy makers and funders in each of our countries are commonly frustrated by the mismatch between the pace of basic scientific discovery and the meagre rate of substantial health improvements. They have often heard of the 'valley of death' in biomedical research, but may not be aware that the field of translational science exists to remedy it. There is therefore an urgent need to increase the understanding of translation among funders and policy makers and the substantial contributions it makes to public health and the economy. The value of continued investment in this field, as well as the greater impact it could have with increased resources, needs to be more consistently communicated on a regional, national and international level to funders and policy makers. By leveraging its global scope and presenting a unified front of leading translational scientists from non-profit organizations and government institutions, this global collaborative effort hopes to communicate critical information to funders and policy makers and to engender greater recognition and appreciation of the field.
Patients, disease advocacy groups and associated community members are integral participants of any translational science team. Translational researchers can learn invaluable information about disease symptomatology and therapeutic priorities from the real-world experiences of patients living with a disease. Involving them in each stage in the development of a new medical intervention will help to catalyse the entire process. Likewise, patients can more effectively engage in and derive value from translational science when they are informed of how the translational science ecosystem operates. This global collaborative initiative will work to further the paradigm in which patients and scientists enable the more rapid development of new treatments by working together.
Another challenge facing translational science is attaining recognition as an independent discipline with unique requisite knowledge and skill sets. Although translational science is multidisciplinary by nature, it is greater than the sum of its parts and requires the integration of the experiences and information from a variety of disciplines into a single practice. The welltrained translational scientist, therefore, may be an expert in a particular aspect of translation (such as pharmacology or epidemiology) but also possesses essential knowledge on the full spectrum of translation and uses it to directly inform their research. The work of such scientists has led to the repurposing of existing drugs to treat new diseases, the shortening of the time it takes to launch clinical trials, the development of innovative technologies to identify promising therapeutic targets, and the creation of public-private partnerships to de-risk early-stage drug candidates. For example, NCATS-funded researchers have rapidly advanced saracatinib, originally developed as a cancer therapy, into clinical studies as a repurposed treatment for Alzheimer disease. TIA has reduced clinical trial start-up time in Australia by providing subsidised access to GCP documentation templates, while scientists supported by EATRIS have developed a novel mass spectrometry technology to facilitate target and biomarker validation in clinical settings. Last, both CDRD and MRCT have established public-private partnerships to accelerate drug development: CDRD has created Innovation Funds with multiple industry and nonprofit stakeholders to support translation of academic innovations, and MRCT has collaborated with pharmaceutical companies to perform critical humanization and optimization studies of therapeutic antibodies, leading to approved drugs such as pembrolizumab. By encouraging the recognition of translational science as a formal field of study, this collaboration hopes to increase the number and diversity of practitioners in the translational workforce.
Outlook
Challenges in the reproducibility of preclinical translational research, the high failure rate of promising new interventions, the lack of scientific understanding or efficient processes throughout the translational process, and uncertainties in the policy and funding landscape all extend beyond geographical borders. No one organization operating in isolation is likely to overcome all of these complex barriers; a concerted international approach is necessary. As part of the collaborative effort introduced in this article, our organizations will take advantage of opportunities to coordinate our endeavours, leverage our combined expertise and resources, share best practices, broadly disseminate our results, and present a unified voice calling for greater recognition of the contributions and support of translational science.
In conclusion, the promise and challenges of the new field of translational science, including those in drug discovery and development, must be brought to the forefront for all stakeholders in the health research system. Integrating and leveraging the cumulative knowledge of translational organizations on a global level promises to more rapidly advance innovative medicines to patients in the many disease areas with high unmet medical need, leading to improved health outcomes for patients, more sustainable health-care systems and overall benefit to society.
